Results 91 to 100 of about 128,993 (222)
Denosumab discontinuation and fracture risk: getting the balance right
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley +1 more source
Dealing with Rising Health Care Costs: The Case of Pharmaceuticals [PDF]
Pharmaceuticals; Advertising; Generic Market Entry; Reference Pricing; Parallel ...
Königbauer, Ingrid
core
Acknowledgement to Reviewers of Pharmaceuticals in 2013
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in ...
Pharmaceuticals Editorial Office
core +1 more source
Acknowledgment to Reviewers of Pharmaceuticals in 2020
Peer review is the driving force of journal development, and reviewers are gatekeepers who ensure that Pharmaceuticals maintains its standards for the high quality of its published papers [...
Pharmaceuticals Editorial Office Pharmaceuticals Editorial Office +2 more
core +1 more source
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Acknowledgement to Reviewers of Pharmaceuticals in 2015
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2015.
Pharmaceuticals Editorial Office
core +1 more source
Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O).
Marina G. Birck +12 more
doaj +1 more source
Acknowledgement to Reviewers of Pharmaceuticals in 2016
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in ...
Pharmaceuticals Editorial Office
core +1 more source
Senile osteoporosis represents one of the most pressing challenges in modern geriatric medicine, characterized by high prevalence, delayed diagnosis, and severe complications such as low-energy fractures, which are associated with disability, loss of ...
Ekaterina N. Dudinskaya +2 more
doaj +1 more source
Capacity building in medicines development and regulation in Africa—Overview on recent progress
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke +7 more
wiley +1 more source

